$SGEN Addl Analyses from ECHELON1 Ph 3 Clinical Trial of ADCETRISÂin Newly Diagnosed Advanced Hodgkin Lymphoma ASH18 httpswww.businesswire.comnewshome20181202005048enSeattleGeneticsHighlightsAdditionalAnalysesECHELON1Phase.XAQRmwzJdJ

$SGEN Add’l Analyses from ECHELON-1 Ph 3 Clinical Trial of ADCETRIS®in Newly Diagnosed Advanced Hodgkin Lymphoma #ASH18 https://www.businesswire.com/news/home/20181202005048/en/Seattle-Genetics-Highlights-Additional-Analyses-ECHELON-1-Phase#.XAQRmwzJdJ

12:09 EST 2 Dec 2018 | Odi Bruckman

$SGEN Add’l Analyses from ECHELON-1 Ph 3 Clinical Trial of ADCETRIS®in Newly Diagnosed Advanced Hodgkin Lymphoma #ASH18 https://www.businesswire.com/news/home/20181202005048/en/Seattle-Genetics-Highlights-Additional-Analyses-ECHELON-1-Phase#.XAQRmwzJdJY.twitter …

More From BioPortfolio on "$SGEN Add’l Analyses from ECHELON-1 Ph 3 Clinical Trial of ADCETRIS®in Newly Diagnosed Advanced Hodgkin Lymphoma #ASH18 https://www.businesswire.com/news/home/20181202005048/en/Seattle-Genetics-Highlights-Additional-Analyses-ECHELON-1-Phase#.XAQRmwzJdJ"